Wednesday, October 09, 2013 9:19:56 AM
http://www.earningsimpact.com/Transcript/83981/RNN/Rexahn-Pharmaceuticals%2c-Inc----15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference#sthash.csD8Vjot.QsZmK2jF.dpbs
Even though Teva adjust terminate collaboration two weeks ago we have already got an interest expressed by a number of major Pharmaceutical companies based on publications and data that's out there with this compound Just to really talk about the relationship with Teva and the termination of the relationship with the Teva as I said, the agreement was signed back in 2009. Teva had invested over $9 million to start the program up and to get it through the first Phase I trial in Europe and through filing IND here in the United States. Once we filed the IND here in United States, Teva had a 45 day option period of which they had to exercise their option on the compound which they did not.
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM